The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.
 
Mitsuru Yokota
Consulting or Advisory Role - Kaken Pharmaceutical
Speakers' Bureau - Covidien/Medtronic; Intuitive Surgical; Johnson & Johnson; Merck Serono; Nihonkayaku
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yoshiaki Nakamura
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); Daiichi Sankyo/UCB Japan (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Saori Mishima
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences
 
Koji Ando
Honoraria - Merck
 
Stephanie Sanchez
Employment - Natera
 
Kim Magee
Employment - Natera
 
Charuta Palsuledesai
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Robert Lentz
Consulting or Advisory Role - Agenus (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Natera (Inst)
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); Guardant Health (Inst); Lilly (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - KAHR Medical
 
Adham Jurdi
Employment - Natera
Stock and Other Ownership Interests - Agenus; Iovance Biotherapeutics; natera; Verastem
 
Alexey Aleshin
Employment - Alameda Health System (I); Natera
Leadership - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Hiroya Taniguchi
Honoraria - Ono Yakuhin; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst)
 
Jun Watanabe
Honoraria - Covidien; Johnson & Johnson/MedTech; Lilly; Takeda; TERUMO
Research Funding - Covidien (Inst); Stryker (Inst); TERUMO (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Yusuke Suwa
No Relationships to Disclose
 
Keiji Hirata
No Relationships to Disclose
 
Naoya Akazawa
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health